TY  - JOUR 
AU  - Isla, D.
AU  - Lopez-Brea, M.
AU  - Espinosa, M.
AU  - Arrabal, N.
AU  - Pérez Parente, Diego
AU  - Carcedo, D.
AU  - Bernabé-Caro, R.
PY  - 2023
SN  - 1478-7547
UR  - http://hdl.handle.net/20.500.11940/21280
AB  - Background: Atezolizumab has recently been approved for first-line treatment of high PD-L1 expression metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with no EGFR or ALK mutations, on the basis of the IMpower110 trial. This study aims to...
LA  - eng
TI  - Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
DO  - 10.1186/s12962-023-00417-z
T2  - Cost Effectiveness and Resource Allocation
VL  - 21
ER  -